<DOC>
	<DOCNO>NCT00233337</DOCNO>
	<brief_summary>This study ass safety efficacy co-artemether treatment acute uncomplicated P. falciparum malaria return non-immune traveller THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Co-artemether Non-immune Travelers</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<criteria>Patients eligible inclusion meet follow criterion : Male female age 18 older ( prior Amendment 1 : 2 year old ) Nonimmune patient suffer acute uncomplicated P. falciparum malaria , mixed infection include P. falciparum , parasitemia le equal 2 % asexual P.falciparum parasite , confirm microscopy use Giemsastained thick film . Nonimmune patient regard spend first five year life , last five year malaria endemic area , acute P. falciparum malaria diagnose past five year . Nonimmune patient receive prophylaxis antimalarial ( exclude halofantrine ) include clear progression acute P. falciparum infection document . Female patient eligible participate study nonchildbearing potential negative pregnancy test ( urine serum ) screening , use acceptable contraceptive method Patients , inform study procedure medication , give write informed consent willing comply study protocol . Patients exclude participation meet follow criterion : Known hypersensitivity artemether lumefantrine Signs/symptoms indicative severe/complicated malaria accord WHO classification ( e.g . cerebral malaria , see Posttext supplement 1 ) Treatment artemisinin derivative within previous 7 day Concurrent administration treatment / prophylaxis malaria Concurrent administration medication potential hemolytic effect Patients take drug metabolize cytochrome isoenzymes CYP3A4 CYP2D6 Received investigational drug last 4 week entry study Severe cardiac impairment ( i.e . evidence exist cardiac conduction defect overt symptom cardiac dysfunction abnormality baseline ECG associate acute malaria ) ; clinically relevant bradycardia congestive cardiac failure reduce leave ventricular ejection fraction ; preexist prolongation QT interval ; history symptomatic cardiac arrhythmia Having receive halofantrine drug know influence cardiac function within 4 week prior Screening visit take drug know prolong QT interval , include class IA III antiarrhythmic , neuroleptic , antidepressive agent , certain antibiotic ( include macrolides , fluoroquinolones , imidazole , triazole antifungal agent ) , certain nonsedating antihistaminics ( terfenadine , astemizole ) cisapride History splenectomy Clinically significant abnormal baseline hematology ( associate acute malaria ) clinical chemistry parameter , include evidence hepatic renal impairment , know disturbance electrolyte balance e.g . hypokalemia hypomagnesaemia Serious , uncontrolled disease ( include serious psychological disorder ) likely interfere study , concomitant disease could mask response treatment Unlikely , opinion investigator , complete dose followup period , evidence alcohol , drug solvent abuse . Women pregnant , lactate childbearing potential use acceptable contraceptive method also exclude . Other protocol inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Malaria , non-immune traveler</keyword>
</DOC>